Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Executive Summary
Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.
You may also be interested in...
Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III
Partnered on chronic heart failure drug omecamtiv mecarbil, Amgen and Cytokinetics took months to design a Phase III trial that would address the needs and concerns of both payers and clinicians.
Novartis Accentuates The Positives Of Heart Failure Drug Entresto At ACC
Clinicians hail the efficacy data behind the new therapy, but some say reimbursement requirements are too onerous, resulting in slow uptake.
FDA Review Of Novartis' Entresto Shows Agency's Practical Side
Pivotal trial of Novartis' sacubitril/valsartan duo in heart failure did not conform to FDA's combination policy, but agency ultimately valued its mortality effect over statistical correctness.